Wheat Germ Supplementation Will Improve Markers of Gut Health, Inflammation, and Insulin Resistance in Overweight Adults
1 other identifier
interventional
42
1 country
1
Brief Summary
The objective of this pilot study is to determine the effects of wheat germ (WG) supplementation on gut health and subsequent effects on markers of inflammation and insulin resistance in overweight individuals. WG is a by-product of wheat processing and an excellent source of omega-3 fatty acids, vitamin E, and fiber. A few studies have shown the health benefits of WG including gut modulatory potential, but the prebiotic functions of WG in humans remain in question and warrant further investigation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2019
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 22, 2019
CompletedStudy Start
First participant enrolled
May 28, 2019
CompletedFirst Posted
Study publicly available on registry
June 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2021
CompletedDecember 7, 2021
December 1, 2021
2.5 years
May 22, 2019
December 6, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Fecal bacteria population
analyzed by 16sRNA sequencing
Change from baseline fecal bacteria at 30 days
Fecal immunoglobulin A
analyzed by enzyme-linked immunoassay
Change from baseline fecal immunoglobulin A at 30 days
Fecal zonulin
analyzed by enzyme-linked immunoassay
Change from baseline fecal zonulin at 30 days
Fecal short chain fatty acids
analyzed by gas chromatography
Change from baseline fecal shortchain fatty acids at 30 days
Secondary Outcomes (4)
Blood glucose
Change from baselineblood glucose at 30 days
blood glycated hemoglobin
Change from baseline blood glycated hemoglobin at 30 days
blood high sensitivity C-reactive protein
Change from baseline blood high sensitivity C-reactive protein at 30 days
blood insulin level
Change from baselineblood insulin level at 30 days
Study Arms (2)
Wheat germ
EXPERIMENTALWheat germ energy balls containing 30 g of wheat germ, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
Control
PLACEBO COMPARATORControl energy ball containing 30 g of cornmeal, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
Interventions
Eligibility Criteria
You may qualify if:
- Healthy overweight (body mass index, BMI, between 25.0 - 30 kg/m2) 18-45 years old
You may not qualify if:
- diagnosed diabetes, heart disease, and cancer tobacco use excessive alcohol use taking mega-doses of antioxidant/vitamin supplements or medications that could interfere with study endpoints such as antibiotics, anti-inflammatory, and glucose-lowering medications major surgery occurring within 6 months pregnant or lactating previous high intake of wheat germ or sensitivity to gluten and wheat products.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nutritional Sciences Department, Oklahoma State University
Stillwater, Oklahoma, 74078, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Edralin Lucas, PhD
Okklahoma State University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- Participants will not know their treatment assignment and energy balls will be in an opaque container.
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 22, 2019
First Posted
June 18, 2019
Study Start
May 28, 2019
Primary Completion
November 30, 2021
Study Completion
November 30, 2021
Last Updated
December 7, 2021
Record last verified: 2021-12
Data Sharing
- IPD Sharing
- Will not share